We are in the 7th month of the SARS-CoV-2 Pandemic in Europe.
Governments are doing what’s necessary to deal with the situation.
More and more governments are initiating strong measures to control the infection rate with SARS-CoV-2. Israel has announced a second lockdown from September 18 for about three weeks.
There is a lot of coverage of European measures in the local news. Also, a lot of information is published about actions taken in the United States. I rarely read anything about the situation in Asia. Is life back to normal in Asia? How is the risk assessment of the novel Corona Virus in Asian countries?
That‘s why I asked a colleague who lives in Shanghai and is one of the best experts in Life Science and Asia in the world. In this webinar/podcast recording, I will talk with Irénée Robins about these topics.
Born in North-Eastern France in 1971, Irénée Robin has been living in China for almost 20 years. Married with three children, genuinely bicultural, he speaks, reads, and writes Mandarin fluently.
After ten years in the financial services industry with the BNP Paribas group, Irénée started his life sciences career in 2003 by joining Shanghai Cathay Biotech, where he established his first Sino-foreign joint venture with a major German specialty chemicals conglomerate,
leading to the creation of Degussa Cathay Biotechnology in Jining, Shandong Province.
From 2006 to 2011, he worked with the Institut Pasteur of Shanghai, an international research venture established by the Chinese Academy of Sciences, the Shanghai municipal government, and Institut Pasteur. Under his tenure, the institute grew from 40 to 240 researchers, with numerous drug/vaccine discovery programs against life-threatening infectious diseases such as HFMD, HCV, and malaria. His efforts were directed at increasing the institute’s financial resources, notably via expanding CSR programs with multinational corporations and successfully applying to European and international grants.
In 2012, as a Senior Representative for the Biotechnology Innovation Organization (BIO), he organized the “BIO Convention in China” in Shanghai.
From 2013 to early 2019, he was the Chief Marketing Officer for Shanghai Newsummit Biopharma, a subsidiary of Shenzhen-listed Zhejiang Yatai Pharmaceuticals (SHE:002370). He attracted more than 30 Western companies onto the Chinese market during those six years through a vast array of transaction types, from in-licensing to co-development, distribution, and service agreements. He also established 4 Sino-foreign joint ventures in 4 different Chinese cities, including China’s most advanced molecular pathology and next-gen cancer diagnostics lab (Shanghai German JV partner) and a first-in-class IVD development venture based on patients’ immune status markers, the use of NGS platforms. He targeted data mining/deep learning algorithms (Guangzhou – French JV partner).
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Irénée Robin (https://www.linkedin.com/in/ireneerobin/)
CS Life Science Invest (https://www.cslifescienceinvest.com/)
VVR Medical (https://www.linkedin.com/company/vvr-international/)
Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g